Enhancement in the protective qualities of gastric mucus with combination therapy of ebrotidine and amoxicillin for H. pylori eradication.
1. Gastric mucus from Helicobacter pylori-positive patients with active chronic gastritis type B, before and after successful combination therapy consisting of the H2 receptor antagonist ebrotidine (400 mg) and amoxicillin (1,000 mg) administered b.i.d., in the morning and at bedtime for a period of 2 weeks followed by administration of ebrotidine alone for the subsequent 4 weeks, was assessed for the changes in physicochemical properties associated with the mucosal protective potential and anti-H. pylori activity. 2. The results of physicochemical measurements revealed that eradication of H. pylori associated with the successful therapy for active chronic gastritis type B with ebrotidine-amoxicillin was accompanied by a 36% increase in gastric mucus hydrogen ion retardation capacity, a 1.5-2.1-fold increase in mucus gel viscosity and a 2.4-fold increase in its hydrophobicity. 3. The beneficial changes brought about by the ebrotidine-amoxicillin therapy in the physical properties of gastric mucus were also manifest in a 2.7-fold enhancement in the proportion of the high-molecular-weight polymeric mucin form responsible for the maintenance of gastric mucus gel integrity. 4. Moreover, assays of H. pylori aggregating titer of gastric mucus revealed that the successful combination therapy with ebrotidine and amoxicillin led to a 3.8-fold increase in mucin anti-H. pylori activity. 5. The results demonstrate that combination therapy with ebrotidine and amoxicillin for H. pylori eradication leads to a marked improvement in the protective qualities of gastric mucus essential for the preservation of mucosal integrity and enhances the inherent mucosal defense against H. pylori infection.
Research Center, University of Medicine and Dentistry of New Jersey, Newark 07103-2400, USA.
B L
BL
Slomiany
J
J
Piotrowski
A
A
Slomiany
J W
JW
Konturek
W W
WW
Domschke
D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D005753:Gastric Mucosa / Q000187:drug effects; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D009093:Mucus / Q000502:physiology*; D010406:Penicillins / Q000627:therapeutic use*; D010539:Permeability; D012995:Solubility; D013844:Thiazoles / Q000627:therapeutic use*; D014783:Viscosity
D000897:Anti-Ulcer Agents; D001557:Benzenesulfonates; D010406:Penicillins; D013844:Thiazoles; D000658:Amoxicillin; C075156:ebrotidine